RNAi-mediated suppression of constitutive pulmonary gene expression by small interfering RNA in mice

Pulmonary Pharmacology and Therapeutics

Volumn 23, Issue 4, 2010, Pages 334-344

  Gutbier, Birgitt ^a   Kube, Stefanie M ^a   Reppe, Katrin ^a   Santel, Ansgar ^b   Lange, Christian ^b   Kaufmann, Jörg ^b   Suttorp, Norbert ^a   Witzenrath, Martin ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Silence Therapeutics GmbH   (Germany)

Author keywords

Functional siRNA delivery; Inhalation; Lung; Mouse; RNA interference; Small interfering RNA

Indexed keywords

ATURNAI; LAMIN B; LIPOPLEX; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UVOMORULIN; VASCULAR ENDOTHELIAL CADHERIN;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; FEMALE; GENE EXPRESSION; GENE REPRESSION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SEQUENCE TAGGED SITE; WESTERN BLOTTING;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, CD; CADHERINS; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; GENE TRANSFER TECHNIQUES; INFLAMMATION; LAMIN TYPE B; LUNG; MICE; MICE, INBRED C57BL; POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TISSUE DISTRIBUTION; TRACHEA;

EID: 77953121167     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2010.03.007     Document Type: Article

References (31)

1. Aleku M., Fisch G., Mopert K., Keil O., Arnold W., Kaufmann J., et al. Intracellular localization of lipoplexed siRNA in vascular endothelial cells of different mouse tissues. Microvasc Res 76 (2008) 31-41
2. Aleku M., Schulz P., Keil O., Santel A., Schaeper U., Dieckhoff B., et al. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res 68 (2008) 9788-9798
3. Beyerle A., Hobel S., Czubayko F., Schulz H., Kissel T., Aigner A., et al. In vitro cytotoxic and immunomodulatory profiling of low molecular weight polyethylenimines for pulmonary application. Toxicol In Vitro 23 (2009) 500-508
4. Beyerle A., Merkel O., Stoeger T., and Kissel T. PEGylation affects cytotoxicity and cell-compatibility of poly(ethylene imine) for lung application: structure-function relationships. Toxicol Appl Pharmacol (2009)
5. Bhandari V., Choo-Wing R., Lee C.G., Zhu Z., Nedrelow J.H., Chupp G.L., et al. Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat Med 12 (2006) 1286-1293
6. Bitko V., Musiyenko A., Shulyayeva O., and Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 11 (2005) 50-55
7. Castanotto D., and Rossi J.J. The promises and pitfalls of RNA-interference-based therapeutics. Nature 457 (2009) 426-433
8. Czauderna F., Fechtner M., Dames S., Aygun H., Klippel A., Pronk G.J., et al. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 31 (2003) 2705-2716
9. de Fougerolles A., Vornlocher H.P., Maraganore J., and Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6 (2007) 443-453
10. DeVincenzo J., Cehelsky J.E., Alvarez R., Elbashir S., Harborth J., Toudjarska I., et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res 77 (2008) 225-231
11. DeVincenzo J.P. RNA interference strategies as therapy for respiratory viral infections. Pediatr Infect Dis J 27 (2008) S118-S122
12. Drolet D.W., Nelson J., Tucker C.E., Zack P.M., Nixon K., Bolin R., et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res 17 (2000) 1503-1510
13. Durcan N., Murphy C., and Cryan S.A. Inhalable siRNA: potential as a therapeutic agent in the lungs. Mol Pharm 5 (2008) 559-566
14. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494-498
15. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., and Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. %19. Nature 391 (1998) 806-811
16. Gao S., Dagnaes-Hansen F., Nielsen E.J., Wengel J., Besenbacher F., Howard K.A., et al. The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther 17 (2009) 1225-1233
17. Garbuzenko O.B., Saad M., Betigeri S., Zhang M., Vetcher A.A., Soldatenkov V.A., et al. Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug. Pharm Res 26 (2009) 382-394
18. Howard K.A., Rahbek U.L., Liu X., Damgaard C.K., Glud S.Z., Andersen M.O., et al. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther 14 (2006) 476-484
19. Judge A.D., Bola G., Lee A.C., and MacLachlan I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 13 (2006) 494-505
20. Kleinman M.E., Yamada K., Takeda A., Chandrasekaran V., Nozaki M., Baffi J.Z., et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452 (2008) 591-597
21. Lomas-Neira J.L., Chung C.S., Wesche D.E., Perl M., and Ayala A. In vivo gene silencing (with siRNA) of pulmonary expression of MIP-2 versus KC results in divergent effects on hemorrhage-induced, neutrophil-mediated septic acute lung injury. J Leukoc Biol 77 (2005) 846-853
22. Moschos S.A., Jones S.W., Perry M.M., Williams A.E., Erjefalt J.S., Turner J.J., et al. Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem 18 (2007) 1450-1459
23. Moschos S.A., Williams A.E., and Lindsay M.A. Cell-penetrating-peptide-mediated siRNA lung delivery. Biochem Soc Trans 35 (2007) 807-810
24. Perl M., Chung C.S., Lomas-Neira J., Rachel T.M., Biffl W.L., Cioffi W.G., et al. Silencing of Fas, but not caspase-8, in lung epithelial cells ameliorates pulmonary apoptosis, inflammation, and neutrophil influx after hemorrhagic shock and sepsis. Am J Pathol 167 (2005) 1545-1559
25. Prakash H., Becker D., Bohme L., Albert L., Witzenrath M., Rosseau S., et al. cIAP-1 controls innate immunity to C. pneumoniae pulmonary infection. PLoS One 4 (2009) e6519
26. Robbins M., Judge A., and MacLachlan I. siRNA and innate immunity. Oligonucleotides 19 (2009) 89-102
27. Santel A., Aleku M., Keil O., Endruschat J., Esche V., Fisch G., et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther 13 (2006) 1222-1234
28. Song E., Lee S.K., Wang J., Ince N., Ouyang N., Min J., et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 9 (2003) 347-351
29. Thomas M., Lu J.J., Chen J., and Klibanov A.M. Non-viral siRNA delivery to the lung. Adv Drug Deliv Rev 59 (2007) 124-133
30. van de Water F.M., Boerman O.C., Wouterse A.C., Peters J.G., Russel F.G., and Masereeuw R. Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos 34 (2006) 1393-1397
31. Whitehead K.A., Langer R., and Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8 (2009) 129-138